	US 12,344,666 B2
	PDGF mutants and methods of use thereof
Princess Imoukhuede, St. Louis, MO (US); and Erik Procko, Urbana, IL (US)
Assigned to Washington University, St. Louis, MO (US); and The Board of Trustees of the University of Illinois, Urbana, IL (US)
Filed by Washington University, St. Louis, MO (US); and The Board of Trustees of the University of Illinois, Urbana, IL (US)
Filed on Jun. 9, 2022, as Appl. No. 17/836,684.
Claims priority of provisional application 63/208,799, filed on Jun. 9, 2021.
Prior Publication US 2023/0050038 A1, Feb. 16, 2023
Int. Cl. A61K 38/18 (2006.01); A61P 27/02 (2006.01); A61P 35/00 (2006.01); C07K 16/22 (2006.01)

CPC C07K 16/22 (2013.01) [A61K 38/1858 (2013.01); A61P 27/02 (2018.01); A61P 35/00 (2018.01); C07K 2317/76 (2013.01)]

20 Claims

1. An isolated polypeptide having an amino acid sequence comprising at least about 93% of SEQ ID NO: 1, wherein the polypeptide binds to a PDGF receptor and/or a VEGF receptor and increases PDGF and/or VEGF signaling in the cell, and wherein the polypeptide comprises at least one amino acid substitution resulting in a higher binding affinity to the receptor than a wild-type PDGF or VEGF polypeptide, wherein the at least one amino acid substitution is selected from the group consisting of: M12R, I13E, K17N, E21Y, V22L, E24R, R28N, R32I, N57Y, Q71M, and T101K, and any other amino acid substitutions are conservative amino acid substitutions or selected from the group consisting of 177F and K98R.